The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched Phase 1 trial of an investigational vaccine designed to protect against respiratory syncytial virus (RSV). The trial will enroll a small group of healthy adult volunteers to examine the safety of an experimental intranasal vaccine and its ability to induce an immune response. The study is being conducted at the Cincinnati Children’s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs).